Compare Davita Inc (DVA) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Lucid Group Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Lucid Group Inc trades at $3.86 (market cap $1.53B). The key difference: Davita Inc is far larger — about 7.4× Lucid Group Inc's market cap, and Davita Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Lucid Group Inc for 45 Days on average.
| DVA | LCID | |
|---|---|---|
Market Cap | $11.28B | $1.53B |
Volume | 650,294 | 12,739,758 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $21.92 |
52-Week Low | $103.87 | $3.82 |
Typical Hold Time | 113 Days | 45 Days |
Enterprise Value | $24.00B | $4.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Lucid Group (LCID) trades at $3.82, down 8.17% with bearish technical signals and negative financial metrics. The company reported significant losses with -249.21% net income margin and missed earnings expectations for three consecutive quarters. Recent developments include strategic partnerships for autonomous vehicles but also product delays and cash burn concerns.
The outlook remains challenging with substantial financial losses and negative cash flow, though analyst consensus suggests potential upside to $7.60. Key risks include execution delays, high cash burn, and competitive pressures in the EV market. The stock faces make-or-break execution challenges in its turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
